Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Pharnext SA


Pépinière Genopole Entreprises
4, rue Pierre Fontaine – Genopole Campus 3
91058 EVRY cedex – FRANCE
Phone: +33 1 60 87 89 48

David HORN SOLOMON: CEO
Web Site >
Pharnext - Genopole's company Pharnext - Genopole's company

#Santé & Bien-être #Therapeutics

  • Genomics
  • Big data
  • Artificial intelligence
  • Network pharmacology
  • Drug repurposing
  • Molecule combinations
  • Biomarkers

Field of Activity


Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS)).

BACKGROUND
Pharnext was founded by renowned scientists and entrepreneurs (including Professor Daniel Cohen, a pioneer in modern genomics) to develop new therapies targeting several key pathological mechanisms in severe orphan and common neurodegenerative diseases.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Pharnext’s approach is applicable to virtually any disorder and particularly suited to multifactorial diseases.
Pharnext is currently focused on neurodegenerative diseases:

  • Charcot-Marie-Tooth (CMT1A) disease: PHASE 3 trial completed – with positive topline results.
  • Alzheimer’s disease: Phase 2a trial completed.
  • ALS: Phase 1 trial completed.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
€91 million in equity raised from a foundation.

  • Listed on the Euronext Growth trading market in July 2016.
  • CMT1A program completed phase 3 trials with positive topline results.

COLLABORATIONS SOUGHT

  • Industrial partnerships in the pharmaceutical sector for Pharnext’s candidate drugs.
  • R&D collaborations with academic and industrial partners for early programs.
  • Further Information

    60 patent families
    45 staff members
    Strengths:
    New paradigm in R&D for faster pharmaceutical developments, particularly in multifactorial diseases. Eminent scientists and breakthrough approaches in pharmacogenomics.
    Innovation assets:
    Innovative drug combinations based on genomic big data and artificial intelligence. Pharnext’s approach can potentially be applied to any disease.

Share
Genopole’s Companies

#Therapeutics


In same field

DeepTope - Genopole's company

Deeptope

– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Discover
Phagos - Genopole's Company

PHAGOS

At Phagos, we use bacteria’s natural predator, the bacteriophage, to overcome infectious diseases in aquaculture.

Discover
Theranovir - Genopole's Company

Theranovir

Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Discover
Wiratech Europe - Genopole's Company

Wiratech Europe

Wiratech Europe is a healthcare company that uses scientific knowledge of human variability and instrumental technologies to provide innovative tests, devices and services.

Discover
Vaccinopole - entreprise génopolitaine

Vaccinopole

Production of BCG vaccines and BCG-based cancer and inflammation treatments, preparation and distribution of fresh log-phase BCG cultures.

Discover
Synsight - Genopole's Company

Synsight

Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Discover
Santen - Genopole's Company

Santen

Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.

Discover
Pymabs - Genopole's Company

Pymabs

R & D services in the field of transient expression of recombinant proteins in plants.

Discover
Pharming - Genopole's company - Logo 2021

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover
PEP-Therapy - Genopole's Company - logo 2021

PEP-Therapy

PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Discover
Genosafe - Genopole's Company

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover
Généthon - Genopole's Laboratory

Généthon

Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.

Discover
Eukarÿs - Genopole's company

Eukarÿs

Synthetic gene therapy for the treatment of severe human liver diseases and tools for the bioproduction of recombinant proteins and viruses using the proprietary expression system C3P3.

Discover
Enterome - Genopole's company

Enterome

Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Discover
Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

Discover
View all >
With the support from